BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21147623)

  • 1. Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients.
    Holownia A; Mroz RM; Skopinski T; Kielek A; Kolodziejczyk A; Chyczewska E; Braszko JJ
    Eur J Med Res; 2010 Nov; 15 Suppl 2(Suppl 2):64-7. PubMed ID: 21147623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium increases PPARγ and decreases CREB in cells isolated from induced sputum of COPD patients.
    Holownia A; Mroz RM; Skopinski T; Kolodziejczyk A; Chyczewska E; Braszko JJ
    Adv Exp Med Biol; 2013; 756():9-14. PubMed ID: 22836613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered histone deacetylase activity and iNOS expression in cells isolated from induced sputum of COPD patients treated with tiotropium.
    Holownia A; Mroz RM; Wielgat P; Skopinski T; Kolodziejczyk A; Sitko A; Chyczewska E; Braszko JJ
    Adv Exp Med Biol; 2013; 788():1-6. PubMed ID: 23835951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tiotropium as new quality medication in the COPD management].
    Lubiński W; Płusa T
    Pol Merkur Lekarski; 2006 Jan; 20(115):5-7. PubMed ID: 16617725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siglec-8 in induced sputum of COPD patients.
    Mroz RM; Holownia A; Wielgat P; Sitko A; Skopinski T; Chyczewska E; Braszko JJ
    Adv Exp Med Biol; 2013; 788():19-23. PubMed ID: 23835953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
    Celli B; ZuWallack R; Wang S; Kesten S
    Chest; 2003 Nov; 124(5):1743-8. PubMed ID: 14605043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J; Akitsu K
    Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small airways ventilation heterogeneity and hyperinflation in COPD: response to tiotropium bromide.
    Verbanck S; Schuermans D; Vincken W
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):625-34. PubMed ID: 18268937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
    ZuWallack AR; ZuWallack RL
    Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
    Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
    Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
    Halpin DM; Kaplan AG; Russell RK
    Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.
    Calverley PM; Lee A; Towse L; van Noord J; Witek TJ; Kelsen S
    Thorax; 2003 Oct; 58(10):855-60. PubMed ID: 14514937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tiotropium on neural respiratory drive during exercise in severe COPD.
    Qin YY; Li RF; Wu GF; Zhu Z; Liu J; Zhou CZ; Guan WJ; Luo JY; Yu XX; Ou YM; Jiang M; Zhong NS; Luo YM
    Pulm Pharmacol Ther; 2015 Feb; 30():51-6. PubMed ID: 25449059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD.
    Tanabe N; Muro S; Oguma T; Sato S; Kiyokawa H; Takahashi T; Kudo M; Kinose D; Kubo T; Hoshino Y; Ogawa E; Hirai T; Mishima M
    COPD; 2012 Aug; 9(4):401-8. PubMed ID: 22509949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
    van Noord JA; Smeets JJ; Custers FL; Korducki L; Cornelissen PJ
    Eur Respir J; 2002 Apr; 19(4):639-44. PubMed ID: 11998992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease.
    Casaburi R; Conoscenti CS
    Am J Med; 2004 Dec; 117 Suppl 12A():33S-40S. PubMed ID: 15693641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
    Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.